

Curriculum Vitae

Personal information



Surname / First name **Aurora Mirabile**
Address Via Toscana, 48 Gorgonzola (MI) Italy
Fax
E-mail
Nationality Italian
Date of birth 22/01/1979
Gender Female

Work experience

Dates From 2019 to now
Main activities and responsibilities Extensor of AIOM National guidelines of head and neck cancers

Dates From 2018 to 2019
Main activities and responsibilities Revisor of AIOM National guidelines of head and neck cancers

Dates From April 2017 to now
Occupation or position held Medical Oncologist with annual contract, Head and neck cancer management referent.
Main activities and responsibilities In-patient and outpatient clinical practice, daily management of cancer patients (in day hospital or oncology department). Involvement in the multidisciplinary management of Head and neck cancer, melanoma and lung cancer patients. Work in the research clinical trial.
Name and address of employer Department of Oncology, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute, Milan

Dates From January 2014 to March 2017
Occupation or position held Assistant medical director
Main activities and responsibilities In-patient and outpatient clinical practice, daily management of cancer patients (in day hospital or oncology department). Involvement in the multidisciplinary management of Head and neck cancer and gastro-intestinal cancer patients. Work in the research clinical trial.
Name and address of employer Medical Oncology Division, AO S. Antonio Abate, Gallarate, Varese Italy

Dates From November 2009 to January 2014

Occupation or position held	Medical oncologist with annual contract
Main activities and responsibilities	In-patient and outpatient clinical practice. Involvement in the multidisciplinary management of Head and neck cancer patients. Work in the research clinical trial.
Name and address of employer	Head and Neck Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy.
Dates	July 2009 – October 2009
Occupation or position held	Specialty training at the Division of Medical Oncology 3
Main activities and responsibilities	In-patient and outpatient clinical practice. Involvement in the multidisciplinary management of Head and neck cancer patients. Work in the research clinical trial.
Name and address of employer	Head and Neck Medical Oncology Unit, Istituto Nazionale Tumori, Milan, Italy.
Dates	September 2006 – July 2009
Occupation or position held	Specialty training at the Division of Medical Oncology 3
Main activities and responsibilities	In-patient and outpatient clinical practice. Involvement in the management of Onco-Haematological clinical patients. Work in the research clinical trial.
Name and address of employer	Bone Marrow Transplantation Unit, Istituto Nazionale Tumori, Milan, Italy.
Dates	March 2004 - September 2006
Occupation or position held	Scholarship
Main activities and responsibilities	Clinical experience in general medical oncology (lung, breast, head and neck and gastrointestinal cancers), weekly journal club attendance and participation into daily discussions of clinical cases. In-patient and outpatient clinical practice. Involvement in the management of oncological clinical patients. Work in the research clinical trial.
Name and address of employer	Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy.
Dates	March 2003 – October 2004
Occupation or position held	Internship at the Division of Medical Oncology
Main activities and responsibilities	Clinical experience in general medical oncology (lung, breast, head and neck and gastrointestinal cancers), weekly journal club attendance and participation into daily discussions of clinical cases. Work in the research clinical trial.
Name and address of employer	Istituto Europeo di Oncologia, Milano, Italy.
Dates	1997 – 1998
Occupation or position held	Internship at the Division of Internal Medicine
Main activities and responsibilities	Clinical experience in internal medicine.
Name and address of employer	Ospedale San Paolo, Milan, Italy.
Education and training	

Date	November 2009
Title of qualification awarded	Medical Oncology Specialization, mark 70/70 cum laude
Principal subjects/occupational skills covered	Title of dissertation: "The dose-intensity relates with the out-come in patients affected by locally advanced head and neck squamocellular carcinoma who underwent to concomitant chemotherapy and radiotherapy: dates of patients treated in INT and in Princess Margaret Hospital of Toronto"
Name and type of organization providing education and training	University of Milan, Italy
Dates	February 2005
Title of qualification awarded	Abilitation, mark 267 / 270
Principal subjects/occupational skills covered	
Name and type of organization providing education and training	University of Milan, Italy.
Dates	October 2004
Title of qualification awarded	MBCChB, mark 108 / 110
Principal subjects/occupational skills covered	Title of dissertation: "Microinvasive breast carcinoma without nodal involvement: the necessity of a personalized treatment ."
Name and type of organization providing education and training	University of Milan, Italy
Dates	1997
Title of qualification awarded	Diploma
Name and type of organization providing education and training	Liceo Classico Statale G. Carducci, Milan, Italy
Dates	1997
Title of qualification awarded	First Certificate in English
Name and type of organization providing education and training	University of Cambridge
Personal skills and competences	
Mother tongue(s)	Italian
Other language(s)	
Self-assessment	
<i>European level (*)</i>	
English	

Understanding		Speaking		Writing			
Listening		Reading		Spoken interaction		Spoken production	
1	B2		B2		B2		B2

	(*) Common European Framework of Reference for Languages					
French	Self-assessment	Understanding		Speaking		Writing
	European level (*)	Listening	Reading	Spoken interaction	Spoken production	
		C	C	C	C	C
	Computer skills	Good practice in Windows 7 and MAC, e-mail, Office and Internet.				
	Affiliations	Partner AIOM since 2011, partner AIOCC since 2016, partner ESMO since 2017, partner EORTC since 2017, Member of IO Young since 2017 partner EHNS since 2019.				
Othew informations		<p>Sub investigator and co-investigator in more than 40 Italian and international trials focused on head and neck cancer patients management.</p> <p>Certified experience in clinical trial management (GCP R2 training certificate 10/05/2017)</p> <p>Teaching activity in the degree course of medicine, dentistry, nursing sciences and in the specialty school of otolaryngology</p> <p>ORGANIZATION OF SCIENTIFIC MEETINGS:</p> <p>- 2018 : Scientific Committee of the « La gestione multidisciplinare del paziente con tumore squamocellulare cervico-facciale localmente avanzato: criticità e linee guida nella pratica clinica. I Edition»</p> <p>- 2019 : Scientific Committee of the « La gestione multidisciplinare del paziente con tumore squamocellulare cervico-facciale localmente avanzato: criticità e linee guida nella pratica clinica. II Edition»</p> <p>H-Index (according to Scopus, Web of Science) = 10 Number of total citations= 277 by 268 documents Number of total publications = 23</p>				

PUBLICATIONS

1. Mirabile A, Biafora M, Giordano L. et al. Uncommon site of metastasis and prolonged survival in patients with anaplastic thyroid carcinoma: a systematic review of the literature. *Cancers (Basel)*. 2020 Sep 10;12(9):2585. Doi: 10.3390/cancers12092585. PMID:32927794;=MCID:PMC7564634.
2. Galli A, Colombo M, Carrara G, et al. Low skeletal muscle mass as predictor of postoperative complications and decreased overall survival in locally advanced head and neck squamous cell carcinoma: the role of ultrasound of rectus femoris muscle [published online ahead of print, 2020 Jun 13]. *Eur Arch Otorhinolaryngol*. 2020;10.1007/s00405-020-06123-3. doi:10.1007/s00405-020-06123-3
3. Mirabile A, Rivoltini L, Daveri E, et al. Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. *Cancers (Basel)*. 2020;12(5):E1153. Published 2020 May 4. doi:10.3390/cancers12051153
4. P. Bossi, M C Merlano, M G Ghi, G Rinaldi, F Casponigro, M Airolidi, A Farnesi, A Cassano, D Ferrari, A Mirabile, A Tosoni, D Galizia, G Moretti, G Calareso, A Vingiani, F Perrone, A Falletta, LF Licitra. A single-arm, open label multicenter, phase IIIb clinical trial with nivolumab in subjects with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck. *Annals of Oncology*, Volume 30, Issue Supplement_5, October 2019, <https://doi.org/10.1093/annonc/mdz252.032>
5. CE Fundakowski ; A Mirabile; **Head and Neck Cancer: Psychological and Psychosocial Effects- The Impact of Pain-** Head and Neck Cancer, 2020 – Springer.
6. Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U, Group IY. **Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.** *Biomed Res Int*. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Review.
7. Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, Gregorc V. **PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review.** *Cancers (Basel)*. 2019 Mar 1;11(3).
8. **Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck.** Mirabile A, Miceli R, Calderone RG, Locati L, Bossi P, Bergamini C, Granata R, Perrone F, Mariani L, Licitra L. *Head Neck*. 2019 Jan 16.
9. **Prevalence, characteristics, and treatment of fatigue in oncological cancer patients in Italy: a cross-sectional study of the Italian Network for Supportive Care in Cancer (NICSO).** Roila F¹, Fumi G², Ruggeri B³, Antonuzzo A⁴, Ripamonti C⁵, Fatigoni S², Cavanna L⁶, Gori S⁷, Fabi A⁸, Marzano N⁹, Graiff C¹⁰, De Sanctis V¹¹, Mirabile A¹², Serpentine S¹³, Bocci C¹⁴, Pino MS¹⁵, Cilenti G¹⁶, Verusio C¹⁷, Ballatori E¹⁸; NICSO (Network Italiano per le Cure di Supporto in Oncologia). *Support Care Cancer*. 2018 Aug 6. doi: 10.1007/s00520-018-4393-9.
10. **Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer.** [Orlandi E¹](#), [Miceli R²](#), [Infante G²](#), [Mirabile A³](#), [Alterio D⁴](#), [Cossu Rocca M⁵](#), et al. *Dysphagia*. 2018 Jun 8. doi: 10.1007/s00455-018-9913-8.
11. **Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?** Lazzari C¹, Karachaliou N², Bulotta A³, Viganó M³, Mirabile A³, Brioschi E³, Santarpia M⁴, Gianni L³, Rosell R⁵, Gregorc V³ *Ther Adv Med Oncol*. 2018 Apr 6;10:1758835918762094. doi: 10.1177/1758835918762094. eCollection 2018.
12. **Role of nutrition in incidence and management of cancer therapy-induced diarrhea (CTID): HEAT (Health Eat and Toxicity) prospective interventional study and preliminary data.** Aurora Mirabile, Erika Vecchio, Stefania Falvella, Lucia Barbarini, Chiara Butti, Fabrizio Ciambelli, Antonella Bovio, Sergio Pauli, Isabella Ricci, Fiorenza Frigo, Elisabetta Del Grosso, Enrica Aloisio, Giovanna Oliva, Salvatore Agatino Artale. May 2017 *Journal of Clinical Oncology* 35(15_suppl):e18251-e18251. DOI: 10.1200/JCO.2017.35.15_suppl.e18251.
13. **Oncological supportive-care unit (OSU): An effective toxicity management model.** Aurora Mirabile, Emanuela Foglia, Fiorenza Frigo, Elisabetta Del Grosso, Lucia Barbarini, Antonella Bovio, Chiara Butti, Fabrizio Ciambelli, Sergio Pauli, Isabella Ricci, Elisabetta Gargiola, Enrica Aloisio, Giovanna Oliva, Salvatore Agatino Artale. May 2017 *Journal of Clinical Oncology* 35(15_suppl):e18301-e18301. DOI: 10.1200/JCO.2017.35.15_suppl.e18301
14. **Report from European Association for the Study of the Liver: HCC Summit, Geneva, Switzerland, 2-5 February 2017.** Sacco R, Mirabile A, Giacomelli L, Bresci G, Attardo S, Cabibbo G. *Future Oncol*. 2017 Jun; 13(15):1297-1300.

22. **Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.** Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F; Italian Group for Antiemetic Research. *Ann Oncol.* 2015 Mar 5.
23. **Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.** Bossi P, Locati L, Bergamini C, Mirabile A, Granata R, Imbimbo M, Resteghini C, Licitra L. *Oral Oncol.* 2014 Jul 4.
24. **Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.** Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M. *Future Oncol.* 2014 Jun 20:1-10.
25. **Prognostic factors in patients (pts) with recurrent and/or metastatic (RM) head and neck carcinoma (HNC) treated with cetuximab plus chemotherapy.** Mirabile A., Bossi P., Cossu Rocca M., Ferrari D., Battisti N., Locati LD., Marcegaglia S., Licitra L. *ECCHNO poster abstract April 2014.*
26. **Surveillance of head and neck cancer (hnc) patients: clinical And radiological exams or symptom driven follow-up?** Imbimbo M., Bossi P., Potepan P., Fallai C., Scaramellini G., Locati L., Orlandi E., Bergamini C., Mirabile A., Granata R., Resteghini C., Licitra L. *I Supplementi di Tumori Vol 14, n°1, Oct 2013*
27. **Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator-initiated phase II trial (NCT01703455).** Laura L., Federica Perrone, Barbara Cortelazzi, Dagrada P., Paolo Bossi, Enrico M. Civelli, Cristiana Bergamini, Pasquale Quattrone, Martina Imbimbo, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Camilla Cassani, Alfonso Marchiano', Gabriella Saibene, Silvana Pilotti. *I Supplementi di Tumori Vol 14, n°1, Oct 2013*
28. **Health care-associated infections (HAIs) in head and neck carcinoma (HNC) patients treated with chemotherapy (CT) and/or radiotherapy (RT).** Aurora Mirabile, Chiara Vismara, Paolo Bossi, Laura D. Locati, Cristiana Bergamini, Roberta Granata, Carlo Resteghini, Daniele Morelli, Paolo Scarpellini, Lisa F. Licitra *J Clin Oncol* 31, 2013 (suppl; abstr 6046)
29. **Sorafenib in recurrent and/or metastatic salivary gland carcinomas (RMSGCs): An investigator-initiated phase II trial (NCT01703455).** Laura D. Locati, Paolo Bossi, Enrico M. Civelli, Federica Perrone, Cristiana Bergamini, Barbara Cortelazzi, Pasquale Quattrone, Martina Imbimbo, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Luigi Mariani, Davide Tosarello, Camilla Cassani, Alfonso Marchiano', Gabriella Saibene, Silvana Pilotti, Lisa F. Licitra *J Clin Oncol* 31, 2013 (suppl; abstr 6020)
30. **Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy.** Paolo Bossi, Loris De Cecco, Federica Perrone, Barbara Cortelazzi, Maria Cossu Rocca, Siano Marco, Andrea Sponghini, Cristiana Bergamini, Laura D. Locati, Aurora Mirabile, Roberta Granata, Carlo Resteghini, Silvana Pilotti, Silvana Canevari, Lisa F. Licitra. *J Clin Oncol* 31, 2013 (suppl; abstr 6027).
31. **Healthcare associated infections in head and neck carcinoma patients treated with chemotherapy and/or radiotherapy.** A. Mirabile, C. Vismara, P. Bossi, L. Locati, C. Bergamini, R. Granata et al. *Ann Oncol.* 2012 Sept, vol 23.
32. **Association between salivary cytokine levels and chemoradiotherapy-induced toxicities in head and neck cancer patients.** Paolo Bossi, Paola Filipazzi, Carlo Resteghini, Rosalba Miceli, Ester Orlandi, Laura Locati, Carlo Fallai, Silvia Tana, Agata Cova, Paola Squarcina, Monica Rodolfo, Cristiana Bergamini, Roberta Granata, Aurora Mirabile, Licia Rivoltini, Lisa F. Licitra; *J Clin Oncol* 30, 2012 (suppl; abstr5555)
33. **Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.** Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, Locati LD, Bossi P, Bergamini C, Mirabile A, Mariani L, Olmi P, Scaramellini G, Potepan P, Quattrone P, Ang KK, Licitra L. *Ann Oncol.* 2012 Jul;23(7)
34. **Targeted therapy in head and neck cancer** Lisa Licitra, Cristiana Bergamini, Aurora Mirabile and Roberta Granata. *Curr Opin Otolaryngol Head Neck Surg.* 2011 Mar 2. 19:132–137

35. **Outcome of Squamous Larynx Cancer (LC) in Patients Aged >70 -a Mono-institutional Case-series Review.** L. Locati, A. Mirabile, P. Bossi, E. Orlandi, G. Scaramellini, S. Riccio, P. Olmi, L. Licitra. European Journal of Cancer Vol. 47 Supplement 1, September 2011.
36. **Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer.** Bossi P, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, Quattrone P, Potepan P, Gloghini A, Miceli R, Mattana F, Scaramellini G, Licitra L. Ann Oncol. 2011 Mar 11.
37. **PROGNOSTIC FACTORS INFLUENCING OUTCOME OF PATIENTS WITH RECURRENT OR METASTATIC CARCINOMA (R&M) OF THE HEAD AND NECK: RESULTS OF AN ITALIAN MONOINSTITUTIONAL STUDY.** A. Mirabile¹, R. Calderone¹, R. Miceli², F. Mattana², L. Locati¹, P. Bossi¹, C. Bergamini¹, R. Granata¹, L. Mariani², L. Licitra¹. I Supplementi di Tumori Vol 10, n°1, Oct 2010.
38. **SURVIVAL OF PATIENT WITH OROPHARYNGEAL CANCER ACCORDING TO HPV STATUS, SMOKE AND TUMOR PRESENTATION: AN ITALIAN VALIDATION STUDY** R. Granata¹, F. Perrone², R. Miceli⁴, M. Franceschini³, E. Orlandi³, P. Bossi¹, L. Locati¹, C. Bergamini¹, R. Calderone¹, A. Mirabile¹, B. Cortelazzi², S. Pilotti², L. Mariani⁴, P. Olmi³, K.K. Ang⁵, L. Licitra¹ Supplementi di Tumori Vol 10, n°1, Oct 2010.
39. **SAMITAL-RADIOTHERAPY (CT-RT) INDUCED MUCOSITIS IN HEAD AND NECK SQUAMOCELLULAR CANCER (HNSCC) PATIENTS (PTS): RESULTS OF A PROSPECTIVE MONOINSTITUTIONAL PHASE II TRIAL.** Bergamini C¹, Bossi P¹, Mirabile A¹, Orlandi E², Franceschini M², Olmi P², Granata R¹, Locati LD¹, Licitra L¹. Annals of Oncology, Supplement 8, Vol 21, Oct 2010.
40. **Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): A matched pair analysis", by Rades et coll.** Bossi P, Granata R, Bergamini C, Mirabile A, Locati L, Licitra L. Oral Oncol. 2010 Oct 15.
41. **PROGNOSTIC FACTORS INFLUENCING OUTCOME OF PATIENTS WITH RECURRENT OR METASTATIC CARCINOMA (R&M) OF THE HEAD AND NECK: RESULTS OF AN ITALIAN MONOINSTITUTIONAL STUDY.** A. Mirabile¹, R. Calderone¹, R. Miceli², F. Mattana², L. Locati¹, P. Bossi¹, C. Bergamini¹, R. Granata¹, L. Mariani², L. Licitra¹. Annals of Oncology, Supplement 8, Vol 21, Oct 2010.
42. **RADIOACTIVE IODINE (131I-RAI)-RESISTANT ADVANCED DIFFERENTIATED THYROID CANCER (DTC): A NATURAL HISTORY OF A MONO-INSTITUTIONAL SERIES** Locati LD¹, Porcu L², Seregini E³, Bossi P¹, Granata R¹, Bergamini C¹, Mirabile A¹, Torri V², Licitra L¹ Annals of Oncology, Supplement 8, Vol 21, Oct 2010.
43. **La terapia bersaglio molecolare nei tumori squamosi della testa & collo**, Lisa Licitra¹, Aurora Mirabile¹ Relazione Ufficiale SIO 2010
44. **Trattamento del dolore cronico in paziente con carcinoma del cavo-orale operato e chemio- radio trattato.** Picone A., Mirabile A., Locati L., Bergamini C., Franceschini M., Granata R., Bossi P., Olmi P., Licitra L. Wolters Kluwer Health Italy 2010
45. **MALT lymphoma and Kaposi Sarcoma in an HIV-negative patient.** Mirabile A, Devizzi L, Gianni AM, Cabras A, Carbone A. Am J. Haematol. 2010 Jun 29
46. **Palonosetron plus dexamethasone for the prevention of emesis induced in patients receiving single and multiple-day high-dose chemotherapy.** M. Di Nicola, A. Mirabile, C. Carlo-Stella, A. Necchi, M. Magni, E. Schiavello, A.M. Gianni. Poster EBMT April 2008.